Applied UV Declares Monthly Preferred Stock Dividend

February 22, 2022 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

Applied UV Enters Three Year Agreement Through its Scandinavian Distribution Partner Airocide Nordic Oy with Plandent Division for Distribution of Airocide(R) to Dental Providers

February 22, 2022 8:00 AM

Covers Finland with plans to expand throughout all of countries in Scandinavia and EuropeMOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and...

Read more

EryDel Appoints Thomas Sabia as Chief Commercial Officer

February 22, 2022 2:00 AM

BRESSO, MI / ACCESSWIRE / February 22, 2022 / EryDel SpA, a global late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology, announced today the appointment of Thomas Sabia as Chief Commercial Officer. In this role, he will join EryDel's experienced team to help the company navigate and execute its commercial strategy, following the...

Read more

Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market

February 21, 2022 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / February 21, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/) announces its plans for entry into the diagnostics market. Enzolytics has filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics. The PCT Application covers the Company's identification of highly conserved antigens and...

Read more

Nomination Committee for Biovica for the 2022 Annual General Meeting

February 18, 2022 8:30 AM

UPPSALA, SWEDEN / ACCESSWIRE / February 18, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)The Nomination Committee prior to the 2022 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2021, and the Chairman of the Board. The Nomination Committee then appoints a...

Read more

Applied UV Applauds New Policy Guidance Issued by the Centers for Medicare & Medicaid Services (CMS)

February 18, 2022 7:45 AM

CMS Unleashes New Tool for Improving Air Quality in Long-term Care Facilities Aimed to Ease Visitation RestrictionsCMS Offering $3,000 Civil Monetary Penalty (CMP) Reimbursement Funds Per FacilityEstimated *60,000 Long-term Care, Assisted Care & HOSPICE FacilitiesMOUNT VERNON, NY / ACCESSWIRE / February 18, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power...

Read more

Invitation to Presentation of BioInvent's Year-end Report 2021

February 18, 2022 3:50 AM

LUND, SWEDEN / ACCESSWIRE / February 18, 2022 / BioInvent International (STO:BINV)Lund, Sweden, February 18, 2022 - BioInvent International AB (Nasdaq Stockholm: BINV) invites to a presentation of the Year-end report 2021 and a telephone conference with CEO Martin Welschof. The presentation will be held in English.When: 2:00 p.m. CET, Wednesday February 23, 2022.Listen to the presentation: https://tv.streamfabriken.com/bioinvent-q4-2021To...

Read more

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

February 17, 2022 8:00 AM

TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company's monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.Edesa reported that more than 25% of the subjects have been...

Read more

Oncology Pharma Expands on Feasibility Studies and Data

February 17, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / February 17, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") wants to expand on a previously announced press release that included results of formulations and data on licensed technology with NanoSmart Pharmaceuticals demonstrating the time release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulations.The...

Read more

enVVeno Medical Announces ISO 13485 Certification

February 16, 2022 9:05 AM

- Achievement of Quality Management System certification represents an important step towards commercializationIRVINE, CA / ACCESSWIRE / February 16, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has received ISO 13485:2016 certification for the Company's Quality Management System (QMS) and its manufacturing facility...

Read more

Hemogenyx Pharmaceuticals PLC Announces HEMO-CAR-T pre-IND Meeting Request

February 16, 2022 2:00 AM

LONDON, UK / ACCESSWIRE / February 16, 2022 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, has received notification from the Food and Drugs Administration ("FDA") that the proposed pre-Investigational New Drug ("pre-IND") meeting relating to the Company's lead product candidate Chimeric Antigen Receptor ("CAR")...

Read more

Hillstream BioPharma Provides Business Review with Key Pipeline Updates

February 14, 2022 9:04 AM

Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinicSuccessful Closing of a $15 million Initial Public Offering on January 14, 2022R&D Day to Review Novel Emerging Pipeline on February 24, 2022BRIDGEWATER, NJ / ACCESSWIRE / February 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting...

Read more

Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

February 14, 2022 9:00 AM

TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2021 and provided an update on its business.During the quarter, Health Canada approved the Phase 3 design of a Phase 2/3 clinical study evaluating the company's monoclonal antibody, designated EB05,...

Read more

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

February 14, 2022 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2022 / Oncology Pharma, Inc. ("The Company") (OTC PINK:ONPH) and Regen BioPharma, Inc. (OTC PINK:RGBP) and (OTC PINK:RGBPP): announced that they intend to work jointly to fast track the development of therapeutic uses related to treatment in humans with pancreatic cancer of Regen's patented ANTIGEN SPECIFIC MRNA CELLULAR CANCER VACCINES ("MRNA Vaccines").In April of 2021 ONPH was granted an exclusive...

Read more

DiviTum(R)TKa Results from PYTHIA Published in EJC

February 14, 2022 5:00 AM

UPPSALA, SWEDEN / ACCESSWIRE / February 14, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Biovica, active in cancer diagnostics, today announces that the positive DiviTum®TKa results from the European multicenter study PYTHIA have been published in the highly ranked peer-reviewed scientific journal European Journal of Cancer (EJC). The results demonstrate a predictive capacity of the assay after only two weeks of...

Read more

SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022

February 11, 2022 7:15 AM

R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestonesBusiness Review on Monday February 14, 2022 to highlight key program developmentsBRIDGEWATER, NJ / ACCESSWIRE / February 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism...

Read more

Apollo Endosurgery to Report Fourth Quarter and Full Year Results on February 22, 2022

February 10, 2022 8:45 AM

AUSTIN, TX / ACCESSWIRE / February 10, 2022 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release financial results for the fourth quarter and full year ended December 31, 2021 on Tuesday, February 22, 2022, after market close.In conjunction with the release,...

Read more

Applied UV Engages Hayden IR to Launch Comprehensive Investor Relations Program

February 8, 2022 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / February 8, 2022 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly and automatically, today announced it has engaged Hayden IR, a highly recognized, national investor...

Read more

Oncology Pharma Gives Update on Technology, Formulation and Data Creation

February 8, 2022 8:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / February 8, 2022 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is pleased to announce that the co-development agreement and ongoing work to advance the licensed technology with Nanosmart has identified that the formulations demonstrate the time-release characteristic that is expected to improve the safety and localization profile of the eventual lead candidate formulation(s). Data...

Read more

Biovica Provides Time-Plan for FDA Submission

February 7, 2022 4:15 PM

UPPSALA, SE / ACCESSWIRE / February 7, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II)Biovica, active in cancer diagnostics, today announces that it has received full feedback from the FDA on its updated 510(k)-application enabling a clear plan for the submission process. Biovica is now aiming for submission in May 2022.As previously announced, Biovica has been waiting for required feedback from the US Food and Drug...

Read more